Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis: Spring House, Pennsylvania Mo ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share.

Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.

Tremfya is being positioned as a successor to $9 billion-a-year blockbuster Stelara – which is due to start losing patent protection next year in the US and 2024 in Europe – but while it is ...

Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA subcutaneous, SC, induction therapy in adults with moderately to ...

Johnson & Johnson (NYSE: JNJ) announced significant advancements in the treatment of moderately to severely active ulcerative colitis (UC) with its drug TREMFYA® (guselkumab). The Phase 3 ASTRO ...

How one Big Pharma ad campaign is incorporating diversity as a driving force in improving the ways drugs are marketed directly to the patients that need them.